Tumor Microenvironment Analysis of Prostate Cancer Metastasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05304858|
Recruitment Status : Recruiting
First Posted : March 31, 2022
Last Update Posted : March 31, 2022
|Condition or disease||Intervention/treatment|
|Recurrent Prostate Cancer||Procedure: Biopsy|
|Study Type :||Observational|
|Estimated Enrollment :||16 participants|
|Official Title:||Connecting Lineage Target Expression and Immune Tumor Microenvironment Analysis of Prostate Cancer Metastasis|
|Actual Study Start Date :||September 15, 2021|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2024|
Participants who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) will volunteer for a biopsy of a site in the body that contains prostate cancer, such as a bone, a lymph node or an organ such as the liver OR are planned to undergo standard of care surgical procedures such as orthopedic surgery or neurosurgery based on a subjects clinical needs.
Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
- Single-Cell RNA Sequencing (scRNAseq) [ Time Frame: 2 years ]Profiling of the tumor microenvironment (TME) through single-cell RNA sequencing (scRNAseq) for deep profiling of the local immune microenvironment in the tumor.
- CyTOF high-parametric mass cytometry [ Time Frame: 2 years ]CyTOF high-parametric mass cytometry for comprehensive profiling of the tumor and the tumor-immune microenvironment at a larger scale.
- Multiplex Immunofluorescence [ Time Frame: 2 years ]Multiplex immunofluorescence using Vectra multispectral microscope for high throughput spatial analysis of the tumor microenvironment.
- Characterization of the expression and receptor density of prostate lineage antigens [ Time Frame: 2 years ]Tumor tissue will be examined through genetic tests in order to determine gene expression of the tumor cells
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05304858
|Contact: Mark N Stein, MDfirstname.lastname@example.org|
|Contact: Research Nurse Navigatoremail@example.com|
|United States, New York|
|Columbia University Medical Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: Research Nurse Navigator 212-342-5162 firstname.lastname@example.org|
|Principal Investigator:||Mark N Stein, MD||Columbia University|